Is ME/CFS Permanent?

In Australia, the NDIS claims that ME/CFS does not cause permanent disability. Here is evidence to the contrary:

Cairns and Hotopf (2005)

Cairns and Hotopf conducted a systematic review of ME/CFS recovery in adults. The mean recovery rate was 5%. A systematic review is considered the highest form of evidence. Unfortunately, Cairns and Hotopf supported graded exercise therapy or cognitive behaviour therapy. However, they did not conduct a systematic review of these therapies. The best practice guidelines now contraindicate graded exercise therapy due to risk of harm. Cognitive behaviour can be helpful when used to support people with chronic illness. However, it is not a treatment for ME/CFS.

Cairns, R., & Hotopf, M. (2005). A systematic review describing the prognosis of chronic fatigue syndrome. Occupational medicine (Oxford, England), 55(1), 20–31. https://doi.org/10.1093/occmed/kqi013

Best practice guidelines:

National Institute for Health and Care Excellence (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management. Royal College of Physicians Guidelines, downloaded from https://www.nice.org.uk/guidance/ng206/chapter/Recommendations#assessment-and-care-and-support-planning-by-an-mecfs-specialist-team, accessed 12 October, 2026.

Baraniuk J. N., Marshall-Gradisnik, S., & Eaton-Fitch, N. (2024). Myalgic encephalomyelitis (Chronic fatigue syndrome): Straight to the point of care. BMJ Best Practice, downloaded from https://bestpractice.bmj.com/topics/en-gb/277, accessed 4 March, 2025.

Centers for Disease Control (2025). Strategies to Prevent Worsening of Symptoms, downloaded from https://www.cdc.gov/me-cfs/hcp/clinical-care/treating-the-most-disruptive-symptoms-first-and-preventing-worsening-of-symptoms.html, accessed 23 February, 2025.

Ghali et al. (2022)

Ghali et al. followed up 168 patients who met the International Consensus Criteria for myalgic encephalomyelitis after 12 months. “Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a long-term debilitating
multisystem condition with poor prognosis… Recovery and improvement rates were 8.3% and
4.8%, respectively.”

Ghali A, Lacout C, Fortrat J-O, Depres K, Ghali M, Lavigne C. Factors Influencing the Prognosis of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Diagnostics. 2022; 12(10):2540. https://doi.org/10.3390/diagnostics12102540

Carruthers, B. M., van de Sande, M. I., De Meirleir, K. L., Klimas, N. G., Broderick, G., Mitchell, T., Staines, D., Powles, A. C., Speight, N., Vallings, R., Bateman, L., Baumgarten-Austrheim, B., Bell, D. S., Carlo-Stella, N., Chia, J., Darragh, A., Jo, D., Lewis, D., Light, A. R., Marshall-Gradisnik, S., … Stevens, S. (2011). Myalgic encephalomyelitis: International Consensus Criteria. Journal of Internal Medicine, 270(4), 327–338. https://doi.org/10.1111/j.1365-2796.2011.02428.x

National Institute for Health and Care Excellence (NICE; 2021)

“ME/CFS[ME] symptoms can be managed but there is currently no cure (non-pharmacological or pharmacological) for ME/CFS.”

National Institute for Health and Care Excellence (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management. Royal College of Physicians Guidelines, downloaded from https://www.nice.org.uk/guidance/ng206/chapter/Recommendations#assessment-and-care-and-support-planning-by-an-mecfs-specialist-team, accessed 12 October, 2026.

Weigel et al. (2025)

“… the impacts of living with ME/CFS[ME] on the health and wellbeing of those affected are profound and prolonged, thereby affirming the largely permanent nature of the condition”

Weigel B, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S (2025) Sustained illness burden over time among Australians with myalgic encephalomyelitis/chronic fatigue syndrome. PLOS ONE 20(12): e0338433. https://doi.org/10.1371/journal.pone.0338433

Baraniuk (2018)

“There are no… curative medications, or treatments for CFS/ME. The primary goals of treatment are to manage symptoms and improve functional capacity.

Baraniuk, J. N. (2018). “Chronic Fatigue Syndrome/Myalgic Encephalomyelitis”. British Medical Journal Best Practice. https://bestpractice.bmj.com/topics/en-gb/277?fbclid=IwAR0kZYbyrMCNCoNhjMIo_lngn_REjyGBOq5gSsXgDZAeA5Xu5ly_5O2iQ9g

Johnston, Staines and Marshall-Gradisnik (2016)

“…there currently remains no successful therapy for the illness.”

Johnston, S. C., Staines, D. R., & Marshall-Gradisnik, S. M. (2016). “Epidemiological characteristics of chronic fatigue syndrome/Myalgic encephalomyelitis in Australian patients”. Clinical Epidemiology, 8, 97-107. doi: 10.2147/CLEP.S96797